RomoloTavani Introduction: The focus of most of our articles is on generating reliable and sustainable income along with decent growth. We publish a monthly article on “5 Relatively Secure And Cheap Dividend Stocks” to highlight some of the best candidates each month. However, that list changes to some extent from month to month since it is based on a specific filtering method, and as the data changes, so does the list. Last week, we published an article on “7 Income Funds” for passive investors. Today' ...

Baxter International, Inc. (BAX) recently announced that it has entered into a definitive agreement to divest its Vantive Kidney Care segment to Carlyle, a global investment firm, for $3.8 billion.In January 2023, Baxter announced its intention to create a standalone kidney care company intended to improve future performance and create value for all stakeholders. In March 2024, Baxter announced that it was in discussions to explore a potential sale of the Kidney Care segment.Following an analysis of the fin ...

Key TakeawaysBaxter shares slid after the company agreed to sell its kidney care division to Carlyle for $3.8 billion in cash.The company plans to use the roughly $3 billion in after-tax proceeds to reduce its debt.Carlyle's investment is being made through a partnership with Atmas Health. Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash. The deal is expected to generate roughly $3 billion ...

Pitchayanan Kongkaew/iStock via Getty Images Introduction 10 months ago, we had advised investors not to get too myopic about the consequences of the early termination of Novo Nordisk’s (NVO) kidney outcome FLOW trial on Baxter International (NYSE:BAX), but rather focus on some of the more favorable tailwinds surrounding the latter. The BAX stock has since continued to coast along just fine and gauging some of the key highlights from the Q2 results which came out yesterday, we feel even more enthused abo ...

Baxter International Inc. (BAX) reported second-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 68 cents, which beat the Zacks Consensus Estimate of 66 cents by 3%. The bottom line improved 23.6% from the year-ago quarter’s level.On a GAAP basis, the company reported a loss per share of 62 cents from continuing operations compared with a loss of 39 cents in the prior-year quarter.Continuing operations exclude Baxter's BioPharma Solutions business, which was divested during the t ...

Baxter International Inc. (NYSE:BAX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Mat ...

For the quarter ended June 2024, Baxter International (BAX) reported revenue of $3.81 billion, up 2.8% over the same period last year. EPS came in at $0.68, compared to $0.55 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.74 billion, representing a surprise of +1.80%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

Baxter International (BAX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.03%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.61 per share when it actually produced earnings of $0.65, delivering a surprise of 6.56%.Over the last fou ...

SECOND-QUARTER 2024 EARNINGS Baxter International Inc. August 6, 2024 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements concerning the company's financial results (including the outlook for third-quarter and full-year 2024) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis ...